{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T04:59:37Z","timestamp":1776142777137,"version":"3.50.1"},"reference-count":41,"publisher":"American Society of Consultant Pharmacists","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["sr care pharm"],"published-print":{"date-parts":[[2026,4,1]]},"abstract":"<jats:p>\n                    <jats:bold>Background:<\/jats:bold>\n                    This case study reviews the use of glucagon-like peptide-1 receptor agonists (GLP-1 RA) for weight management in older adults. A 69-year-old male patient discusses weight loss goals with his health care provider and seeks pharmacotherapy options in addition to\n lifestyle modifications. His medical history includes type 2 diabetes mellitus (T2D), coronary artery disease (CAD), prior coronary artery bypass graft, heart failure with reduced ejection fraction (HFrEF), hypertension, hyperlipidemia, and allergic rhinitis. He initiated weight loss efforts\n following a myocardial infarction; however, dietary and physical activity changes alone have not resulted in substantial weight reduction.\n                    <jats:bold>Assessment:<\/jats:bold>\n                    This patient is an appropriate candidate for GLP-1 RA therapy given his T2D, obesity, CAD, and a recent elevation in serum\n creatinine (SCr). The patient will initiate semaglutide, a medication approved for weight management with demonstrated cardiovascular benefit. The dose will be titrated to a maintenance dose of 2 mg once weekly, with ongoing monitoring of tolerability and weight loss.Given his age, there\n is concern for sarcopenia associated with excessive weight loss. The patient will be advised to maintain a balanced diet with an emphasis on protein intake and to engage in regular physical activity to minimize loss of muscle mass.\n                    <jats:bold>Outcome:<\/jats:bold>\n                    The patient experiences weight\n reduction within the first few weeks of therapy and tolerates treatment well. He has incorporated additional strength training into his exercise routine and increased his intake of vegetables and protein. The patient has insurance coverage for semaglutide due to his comorbid T2D; therefore,\n medication cost is not a barrier to treatment.\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    When evaluating the use of GLP-1 RA agents in older adults, these agents demonstrate benefits beyond glycemic control and weight loss, including cardiovascular and renal outcomes. However, GLP-1 RA-associated weight\n loss may contribute to muscle loss, which is of particular concern in older adults who are at risk for frailty or falls. Patients receiving GLP-1 RA therapy should be encouraged to maintain adequate protein intake and engage in regular physical activity, particularly resistance training, to\n preserve muscle mass. Additionally, the high cost of GLP-1 RA agents may limit access for patients without insurance.\n                  <\/jats:p>","DOI":"10.4140\/tcp.n.2026.78","type":"journal-article","created":{"date-parts":[[2026,4,12]],"date-time":"2026-04-12T04:30:33Z","timestamp":1775968233000},"page":"78-87","source":"Crossref","is-referenced-by-count":0,"title":["Geriatric Pharmacotherapy Case Series: GLP-1 RA for Weight Management in Older Adults"],"prefix":"10.4140","volume":"41","author":[{"given":"Lauren","family":"Toma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelsey","family":"Buckley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Early","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2625","reference":[{"issue":"2","key":"ref1","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1001\/jama.2021.23619","article-title":"Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes.","volume":"327","year":"2022","journal-title":"JAMA"},{"key":"ref2","article-title":"Compare and contrast the glucagon-like peptide-1 receptor agonists.","year":"2024","journal-title":"StatPearls."},{"key":"ref3","article-title":"Health risks of overweight & obesity.","year":"2023"},{"issue":"1","key":"ref4","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3390\/cells13010065","article-title":"GLP-1 receptor agonists\u2014effects beyond obesity and diabetes.","volume":"13","year":"2023","journal-title":"Cells"},{"key":"ref5","article-title":"Tirzepatide. StatPearls [Internet].","year":"2024"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"108737","DOI":"10.1016\/j.diabres.2021.108737","article-title":"GLP-1 receptor agonists and SGLT2 inhibitors for older people with type 2 diabetes: A systematic review and meta-analysis.","volume":"174","year":"2021","journal-title":"Diabetes Res Clin Pract"},{"issue":"6","key":"ref7","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1161\/CIRCULATIONAHA.123.067584","article-title":"Estimated lifetime cardiovascular, kidney, and mortality benefits of combination treatment with SGLT2 inhibitors, GLP-1 receptor agonists, and nonsteroidal MRA compared with conventional care in patients with type 2 diabetes and albuminuria.","volume":"149","year":"2024","journal-title":"Circulation"},{"issue":"24","key":"ref8","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1161\/CIRCULATIONAHA.122.059595","article-title":"GLP-1 receptor agonists for the reduction of atherosclerotic cardiovascular risk in patients with type 2 diabetes.","volume":"146","year":"2022","journal-title":"Circulation"},{"issue":"1","key":"ref9","article-title":"Cost-effectiveness of GLP-1 receptor agonists versus insulin for the treatment of type 2 diabetes: A real-world study and systematic review.","volume":"20","year":"2021","journal-title":"Cardiovasc Diabetol"},{"issue":"20","key":"ref10","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1001\/jama.2023.19897","article-title":"Obesity management in adults.","volume":"330","year":"2023","journal-title":"JAMA"},{"issue":"10354","key":"ref11","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0140-6736(22)01429-5","article-title":"SGLT2 inhibitors in patients with heart failure: A comprehensive meta-analysis of five randomised controlled trials.","volume":"400","year":"2022","journal-title":"Lancet"},{"issue":"10","key":"ref12","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1111\/dom.12982","article-title":"Combination therapy with GLP-1 receptor agonist and SGLT2 inhibitor.","volume":"19","year":"2017","journal-title":"Diabetes Obes Metab"},{"issue":"Suppl 1","key":"ref13","first-page":"S86","article-title":"Facilitating positive health behaviors and wellbeing to improve health outcomes: Standards of care in diabetes\u20142025.","volume":"48","year":"2025","journal-title":"Diabetes Care."},{"issue":"1","key":"ref14","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1097\/01.NAJ.0000815440.19544.ed","article-title":"Addressing what matters.","volume":"122","year":"2022","journal-title":"Am J Nurs."},{"key":"ref15","article-title":"Age-friendly health systems: The 4Ms.","year":"2019","journal-title":"Hartford Institute for Geriatric Nursing."},{"issue":"Suppl 1","key":"ref16","first-page":"S214","article-title":"Older adults: Standards of Care in Diabetes\u20142026.","volume":"49","year":"2026","journal-title":"Diabetes Care."},{"issue":"2","key":"ref17","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes.","volume":"391","year":"2024","journal-title":"N Engl J Med"},{"issue":"22","key":"ref18","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1161\/CIRCULATIONAHA.124.071689","article-title":"Cardiovascular, kidney, and safety outcomes with GLP-1 receptor agonists alone and in combination with SGLT2 inhibitors in type 2 diabetes: A systematic review and meta-analysis.","volume":"150","year":"2024","journal-title":"Circulation"},{"issue":"Suppl 1","key":"ref19","first-page":"S61","article-title":"Comprehensive medical evaluation and assessment of comorbidities: Standards of Care in Diabetes\u20142026.","volume":"49","year":"2026","journal-title":"Diabetes Care."},{"issue":"S4","key":"ref20","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/dom.15728","article-title":"Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies.","volume":"26","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.2147\/CIA.S297494","article-title":"Diabetic retinopathy in the aging population: a perspective of pathogenesis and treatment.","volume":"16","year":"2021","journal-title":"Clin Interv Aging"},{"issue":"10","key":"ref22","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1007\/s00125-023-05988-3","article-title":"Incretins and microvascular complications of diabetes: neuropathy, nephropathy, retinopathy and microangiopathy.","volume":"66","year":"2023","journal-title":"Diabetologia"},{"issue":"1","key":"ref23","article-title":"Discontinuation and reinitiation of dual-labeled GLP-1 receptor agonists among US adults with overweight or obesity.","volume":"8","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"11","key":"ref24","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.2337\/dci24-0003","article-title":"Efficacy and safety of GLP-1 medicines for type 2 diabetes and obesity.","volume":"47","year":"2024","journal-title":"Diabetes Care"},{"key":"ref25","article-title":"Statement on compounded incretin products.","year":"2024"},{"issue":"1","key":"ref26","article-title":"Trajectory of the body weight after drug discontinuation in the treatment of anti-obesity medications.","volume":"23","year":"2025","journal-title":"BMC Med"},{"issue":"Suppl 1","key":"ref27","first-page":"S183","article-title":"Pharmacologic approaches to glycemic treatment: Standards of care in diabetes\u20142026.","volume":"49","year":"2026","journal-title":"Diabetes Care."},{"key":"ref28","article-title":"What is Ozempic\u00ae? Novo Nordisk;","year":"2025"},{"issue":"4","key":"ref29","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1177\/87551225221092681","article-title":"Once-weekly semaglutide for weight management: A clinical review.","volume":"38","year":"2022","journal-title":"J Pharm Technol"},{"key":"ref30","article-title":"AASLD applauds FDA approval of first GLP-1 therapy for MASH, expanding use of popular weight loss drug to liver disease.","year":"2025"},{"key":"ref31","article-title":"Once-Daily RYBELSUS\u00ae tablets 7 mg or 14 mg.","year":"2025"},{"issue":"1","key":"ref32","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1001\/jama.2023.24945","article-title":"Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: The SURMOUNT-4 randomized clinical trial.","volume":"331","year":"2024","journal-title":"JAMA"},{"issue":"5","key":"ref33","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa2410027","article-title":"Tirzepatide for heart failure with preserved ejection fraction and obesity.","volume":"392","year":"2025","journal-title":"N Engl J Med"},{"key":"ref34","first-page":"2025","article-title":"What is Zepbound? Eli Lilly;","year":"2025"},{"key":"ref35","first-page":"2025","article-title":"FDA approves first medication for obstructive sleep apnea.","year":"2024"},{"issue":"1","key":"ref36","first-page":"3","article-title":"Liraglutide for weight management: A critical review of the evidence.","volume":"3","year":"2016","journal-title":"Obes Sci Pract"},{"issue":"10148","key":"ref37","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0140-6736(18)31773-2","article-title":"Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: A randomized, double-blind, placebo and active controlled, dose-ranging, phase 2 trial.","volume":"392","year":"2018","journal-title":"Lancet"},{"key":"ref38","article-title":"How Saxenda\u00ae works.","year":"2025"},{"key":"ref39","article-title":"Teva announces launch of authorized generic of Victoza\u00ae (Liraglutide Injection 1.8mg), in the United States.","year":"2024"},{"issue":"S2","key":"ref40","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/dom.16364","article-title":"Real-world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP-1RA-based weight-loss therapies.","volume":"27","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"ref41","first-page":"2025","volume":"23","year":"2025","journal-title":"Accessed September"}],"container-title":["The Senior Care Pharmacist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ingentaconnect.com\/content\/ascp\/tscp\/2026\/00000041\/00000003\/art00002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T04:31:00Z","timestamp":1776141060000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ingentaconnect.com\/content\/10.4140\/TCP.n.2026.78"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,1]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,4,1]]}},"alternative-id":["2639-9636(20260401)41:3L.78;1-"],"URL":"https:\/\/doi.org\/10.4140\/tcp.n.2026.78","relation":{},"ISSN":["2639-9636"],"issn-type":[{"value":"2639-9636","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4,1]]}}}